Nassarius Capital
Long/short equity

ResMed: CMS Takes Rungs Out Of Ladder

ResMed's (NYSE:RMD) streak of 72 quarters of y/y revenue growth is in jeopardy. Beginning July 1st, CMS cuts of 47% for CPAP-related equipment should diminish ResMed's first mover pricing advantage and end its revenue growth trend. We believe these future industry headwinds will outweigh growth opportunities and result in ResMed's inflated valuation compressing to comparable levels. Our twelve-month price target of $37 for RMD is based on a forward P/E of 17x.

Company and Industry Overview

ResMed is a pure-play in the growing sleep-disordered breathing space with a market cap of $6.3 billion. It's a leading supplier of continuous positive air pressure (CPAP) devices and masks/accessories that treat obstructive and central sleep apnea. The business model is designed

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details